Navigation Links
Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Date:5/22/2008

- Lead Candidate, RDEA806, Demonstrated No Reproductive Toxicity in

Preclinical Study - - RDEA427 Selected as Clinical Candidate, Demonstrated a 40 Hour Half-Life

with Potential for Once Daily Oral Dosing -

SAN DIEGO, May 22 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced preclinical data on its lead non-nucleoside reverse transcriptase inhibitor (NNRTI) candidate, RDEA806, demonstrating no reproductive toxicity. In addition, novel second-generation NNRTI, RDEA427, was selected as a development candidate for the potential treatment of the human-immunodeficiency virus (HIV), the causative agent of AIDS.

Animal reproductive toxicity studies recently completed with RDEA806 have demonstrated no effects on male or female fertility or on early embryonic development at all tested doses. These results are in contrast to the fetal malformations reported in other NNRTI animal reproductive toxicity studies.

Exploratory human testing (Phase 0) of RDEA427 was recently completed in which micro-doses of the compound were administered to healthy volunteers. Preliminary pharmacokinetic data from this study, produced by Vitalea Science, Inc. using Accelerator Mass Spectrometry (AMS) technology, demonstrated that RDEA427 has a half-life of approximately 40 hours, which could permit once daily oral dosing.

"The ability to use RDEA806 in women, without the risk of birth defects, is a major advantage over the current first-line NNRTI. Women make up 26% of HIV/AIDS diagnosed patients in the United States, and an even larger percent of infected patients worldwide. These preclinical data for RDEA806 further strengthen its impressive product profile," said
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
2. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
3. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
4. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
5. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
6. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
7. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014 Reinforcing its commitment ... (NYSE: PHG AEX: PHIA) today ... Administration (FDA) for its IQon Spectral CT , ... first-of-its kind technology adds a new dimension to Computed ... ability to characterize structures based on their material content ...
(Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. ... Piper Jaffray Healthcare Conference in New York ... a.m. PDT . Dr. Helen Torley , President ... The presentation will be webcast through the "Investors" section ... recording will be made available for 90 days following the ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
(Date:11/26/2014)... 2014 Bunion Bootie, the newest and ... an early celebration of the early holiday shopping season. ... at the promotional price of $29.95 each (normally $33.95 ... to any automatic discounts applied when buying more than ... for complete details. It’s simple: purchasing more Bunion ...
(Date:11/26/2014)... Louisiana Back Institute, leaders of ... minimally invasive spine surgery, announces today the addition ... growing provider network of orthopedic spine surgeons and ... the network’s continuing success providing the most innovative ... who are suffering from orthopedic spine conditions and ...
(Date:11/26/2014)... Sonoran Vein and Endovascular nurse, Jennifer E. ... Award from The American Association of Nurse ... of nurse practitioners. The Distinguished Preceptorship Award recognizes ... a significant contribution toward increasing the awareness and ... Practitioners (AANP) is the largest full-service national professional ...
(Date:11/26/2014)... -- Youngsters who enter puberty early are at increased ... puberty was linked with a number of factors associated ... levels, according to the researchers. Early puberty was also ... and peers, and having friends who were prone to ... study found an association between early puberty and these ...
(Date:11/26/2014)... Teens prescribed anti-anxiety or sleep medications are much ... teens, a new study warns. The findings ... on teenagers before prescribing these drugs to them, ... realize the abuse potential," said lead researcher Carol ... School of Nursing. "These drugs produce highly attractive ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... , , , , ... Inc. (NYSE: DVA ), a leading provider of kidney ... announced its nocturnal dialysis patient population has reached a milestone, with ... DaVita(R) centers around the nation. DaVita has one of the largest ...
... , WASHINGTON, Aug. 28 The Catholic Health ... a goal of health coverage for all people in the United ... under consideration. , , "Our message has always ... office of the association. "Health care must respect and protect human ...
... after, and protect liver from damage, experts say , FRIDAY, ... lots of water, get plenty of rest -- and eat ... the amino acids and minerals in asparagus extract may ease ... , Researchers at the Institute of Medical Science and Jeju ...
... disease, research shows , FRIDAY, Aug. 28 (HealthDay News) -- ... help doctors identify patients at high risk of suffering another ... in the ankle to that in the arm. A significant ... suffers from peripheral artery disease, caused by fatty plaque buildup ...
... Our vocabulary continues to grow and expand even in adulthood. Just ... and now we no longer remember when we heard this word ... some stage new words become just as familiar to us as ... in the Academy of Finland,s Neuroscience Research Programme (NEURO) is how ...
... and the University of Pittsburgh Medical Center will be ... conjunction with the G20 Pittsburgh Summit Sept. 24-25. These ... how and why the "eds and meds" sector of ... region,s success. The Eds-Meds program will begin at ...
Cached Medicine News:Health News:DaVita Offers Dialysis While Patients Sleep 2Health News:DaVita Offers Dialysis While Patients Sleep 3Health News:Catholic Health Association Reaffirms Long-Standing Commitment to Reform Health Care But Waits to Endorse Any Specific Bill 2Health News:Asparagus May Ease Hangover 2Health News:Ankle Circulation Could Warn of Future Strokes 2Health News:Familiar and newly learned words are processed by the same neural networks in the brain 2
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
Medicine Products: